SBIR-STTR Award

Characterization of the Metabolic Competency of Centrifugal Bioreactors
Award last edited on: 3/29/2022

Sponsored Program
SBIR
Awarding Agency
NSF
Total Award Amount
$599,719
Award Phase
2
Solicitation Topic Code
-----

Principal Investigator
Firoz Mistry

Company Information

KBI BioPharma Inc (AKA: Kinetic Biosystems Inc)

1101 Hamlin Road
Durham, NC 27704
   (919) 479-9898
   sales@kbibiopharma.com
   www.kbibiopharma.com
Location: Single
Congr. District: 01
County: Durham

Phase I

Contract Number: ----------
Start Date: ----    Completed: ----
Phase I year
2003
Phase I Amount
$99,719
This Small Business Innovation Research (SBIR) Phase I project proposes to examine the biochemical and metabolic characteristics of a novel Centrifugal Bioreactor (CBR) used to culture suspension mammalian cells. The CBR achieves suspension of animal cells at densities greater than 10 8 cells/mL in a fluidized bed where nutrient liquid flow forces counteract centrifugal forces. The phase I overall goal is to provide a solid scientific understanding of the CBR culture process. The specific technical objectives include measuring the growth rate of a representative cell line in the CBR , establishing steady-state operation of the CBR in terms of nutrient consumption and metabolite production by the cells and manipulating the steady state by changing the dissolved oxygen concentration at the CBR inlet. The commercial application of this project will be in the area of animal cell culture bioreactors. The principal impact of the proposed technology will be to reduce the scale and capital costs of commercial animal cell culture equipment and to potentially improve the quality and consistency of secreted protein product

Phase II

Contract Number: ----------
Start Date: ----    Completed: ----
Phase II year
2004
Phase II Amount
$500,000
This Small Business Innovation Research Phase II project is to develop a pilot-scale Centrifugal Bioreactor (CBR) for the continuous cultivation of hybridoma cells. The commercial application of this project will be in the biopharmaceutical industry for cell culture production of therapeutic agents. It is expected that the technology will reduce the scale and capital costs of commercial animal cell culture equipment and improve the quality and consistency of the secreted protein product